Cancer Immunotherapy

May 29-June 2, 2015; Chicago, Illinois
Core faculty, Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, provide their analysis of key immunotherapy presentations from the 2015 clinical oncology meeting in Chicago along with insight from experts David F. McDermott, MD; Daniel P. Petrylak, MD; Naiyer Rizvi, MD; and Heather Wakelee, MD.
Michael Atkins Headshot
Michael B. Atkins, MD
David F. McDermott, MD
Daniel P. Petrylak, MD
Antoni Ribas, MD, PhD
person default
Naiyer Rizvi, MD
person default
Heather Wakelee, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: August 25, 2015 Expiration: August 24, 2016

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal immunotherapies based on the latest clinical trial data on emerging immunotherapy agents for the management of patients with cancer
  • Identify subpopulations of patients with cancer most likely to benefit from immunotherapy based on prognostic or predictive markers
  • Describe new data on investigational immunotherapeutic agents and approaches with potential importance in the treatment of patients with cancer

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Michael B. Atkins, MD

Deputy Director
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Michael B. Atkins, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, and Novartis.
David F. McDermott, MD

Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber Harvard Cancer Center
Boston, Massachusetts

David F. McDermott, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Genentech, Merck, Novartis, and Pfizer.
Daniel P. Petrylak, MD

Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Pfizer, and sanofi-aventis and funds for research support from Celgene, Dendreon, Johnson & Johnson, Millennium, OncoGeneX, Progenies, and sanofi-aventis.
Antoni Ribas, MD, PhD

Professor
Department of Medicine and Hematology-Oncology
University of California, Los Angeles
Los Angeles, California

Antoni Ribas, MD, PhD, has disclosed that he has received consulting fees from Amgen, Merck, Millennium, Pfizer, and Roche and has ownership interest in Kite Pharma.
Naiyer Rizvi, MD

Professor of Medicine
Price Chair of Thoracic Translational Oncology

Director of Thoracic Oncology
Director of Immuno-Oncology
Columbia University Medical Center
New York, New York

Naiyer Rizvi, MD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Merck, and Roche.
Heather Wakelee, MD

Associate Professor of Medicine, Oncology
Department of Medicine/Oncology
Stanford University
Stanford, California

Heather Wakelee, MD, has disclosed that she has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Celgene, Clovis, Medimmune, Novartis, Pfizer, Roche/Genentech, and Xcovery and consulting fees from Peregrine.

Staff

Gordon Kelley

Senior Clinical Editor

Gordon Kelly has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Kristen M. Rosenthal, PhD

Managing Editor

Kristen M. Rosenthal, PhD, has no real or apparent conflicts of interest to report.
Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, Debbie Price, Registration Database Administrator, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals who provide care for patients with cancer.

Goal

The goal of this activity is to improve participants’ competence in using immunotherapy to treat patients with cancer by applying the most recent data from ASCO 2015.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 25, 2015, through August 24, 2016:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

James K. Kochenderfer, MD Released: December 6, 2019

In this slideset from Clinical Care Options, experts provide insights into the optimal management of toxicities associated with CAR T-cell therapy.

Matthew J. Frigault, MD Released: December 6, 2019

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for lymphomas.

person default Stephen J. Schuster, MD Released: December 6, 2019

In this slideset from Clinical Care Options, experts provide insights on the optimal use of CAR T-cell therapy for ALL.

Jae H. Park, MD Released: December 6, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?